Navigation Links
A Blood Sample Predicts if Cancer Patients Respond to Therapy
Date:5/2/2013

STOCKHOLM, May 2, 2013 /PRNewswire/ --

Karolinska Institutet and University Hospital have shown that a simple blood test can predict breast cancer patients response to therapy, how long treatment will be effective and survival. The results are being presented at the IMPAKT scientific conference in Brussels, May 2-4. The analysis measures growth rate and this is the first time ever that one test have documented this by analysing a blood sample.

     (Photo: http://photos.prnewswire.com/prnh/20130502/612873 )

The study (called TEX) included 287 women with breast cancer who were treated with two different kinds of chemotherapy. The test, DiviTum™, analyses cell-division rate in blood taken from patients before treatment initiation. Regardless of therapy, DiviTum™ predicted which groups of patients who would respond to treatment or not. Patients with tumours that expressed a low DiviTum™-value lived significantly longer, 38 months, compared to 21 months for those with high values.

"By analysing the growth rate in a blood sample we can receive new, valuable clinical information on patient risk and ability to respond to treatment. With DiviTum™ there is an opportunity to identify patients who are at high risk for progression, and this group possibly requires more intense or different treatment", says Thomas Hatschek , lead investigator for the study and Associate Professor at Karolinska Institutet.

"We are keen to look at more possibilities to use DiviTum™ and we will test whether the technology also can be used initially, after starting therapy, to predict and monitor the effect of a chosen treatment. This would at an early stage be a tool to determine whether treatment is appropriate or not. The fact that it only takes a blood sample is an advantage because other methods require tumour tissue", says Thomas Hatschek .

 "We look forward to continued collaboration with Karolinska Institutet, contributing to improved diagnostics and monitoring of cancer patients. It's very positive that the information DiviTum™ provides can give a more comprehensive picture of the disease", says Anders Rylander , CEO Biovica.

Biovica is a bio-diagnostic company, founded in 2009 and ISO 13485 certified for Quality Management Systems. DiviTum™ is CE labelled and MPA registered.
See also http://www.biovica.com


For more information:
Thomas Hatschek , Associate Professor at Radiumhemmet, Karolinska University Hospital & Karolinska Institutet, Department of Oncology-pathology.
Mobile phone: + 46-(0)709-24-43-41      
e-mail: thomas.hatschek@karolinska.se

Anders Rylander , CEO Biovica.
Mobile phone: +46-(0)761-61-21-90    
e-mail: anders.rylander@biovica.com



'/>"/>
SOURCE Biovica International AB
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. FindTheBest Helps Parents Find Cord Blood Banks
2. Cord Blood America Announces DTCC Removes "Chill" Imposed in December 2010
3. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
4. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
5. Study finds chronic abnormal brain blood flow in Gulf War veterans
6. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
7. Cord Blood America Announces Exclusive Agreement With National Childrens Leukemia Foundation to Store Stem Cells
8. Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development
9. NxStage Extends Agreement to Supply Streamline Bloodlines, MasterGuard and Buttonhole Needle Technology to B. Braun
10. Quest Diagnostics STRATIFY JCV™ First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients
11. Improved Cord Blood Processing Research on BioLife Solutions CryoStor® Published in TRANSFUSION
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016 On Thursday, February ... information source for community, health and disaster services, and ... will integrate to enhance care coordination and service delivery ... services they need and to better connect service providers ... San Diego has handled ...
(Date:2/4/2016)... - New FDA action date of July ... of July 22, 2016   --> ... 2016   - Lifitegrast has the potential to ... treatment of signs and symptoms of dry eye disease in adults ... the only product approved in the U.S. in the past decade indicated for the treatment ...
(Date:2/4/2016)... , Feb. 4, 2016 Beike Biotechnology, ... various medical institutions attended a ceremony in late 2015 ... personalized cell therapy in 2016. --> ... Clinical Translation Platform for Personalized Cell Therapy" was hosted ... Cell Production Center, both subsidiaries of Beike Biotechnology Co., ...
(Date:2/4/2016)... -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a ... targeted antiviral therapies, announced today that it will present ... held February 8-9, 2016, at the Waldorf Astoria New ... Healthcare Conference, taking place in New York ... Sapirstein , Chief Executive Officer of ContraVir, will provide ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016 Checkpoint Inhibitors ... Rising Market Are you interested in the ... revenues for checkpoint inhibitors. Visiongain,s report gives those ... product and national level. Avoid falling behind ... progress, opportunities and revenues those emerging cancer therapies ...
(Date:2/1/2016)... Rising sales of consumer electronics ... intuitive gesture control market size ... consumer electronics coupled with new technological advancements to drive ... through 2020   --> ... advancements to drive global touchfree intuitive gesture control market ...
(Date:1/27/2016)... Ohio , Jan. 27, 2016  Rite Track, ... based in West Chester, Ohio ... award winning service staff, based in Austin, ... capacity and ability to provide modifications, installations and technical ... Dovalina , CEO of PLUS, commented, "PLUS has provided ...
Breaking Biology News(10 mins):